Holen Sie sich die Stockscreener-App
16.19
0.37%
0.06
Handel nachbörslich:
16.20
0.010
+0.06%
Schlusskurs vom Vortag:
$16.13
Offen:
$16.27
24-Stunden-Volumen:
1.44M
Relative Volume:
0.66
Marktkapitalisierung:
$1.39B
Einnahmen:
$139.71M
Nettoeinkommen (Verlust:
$-209.36M
KGV:
-5.4696
EPS:
-2.96
Netto-Cashflow:
$-160.60M
1W Leistung:
-0.80%
1M Leistung:
+55.97%
6M Leistung:
+12.59%
1J Leistung:
-17.61%
1-Tages-Spanne:
$15.83
$16.47
1-Wochen-Bereich:
$15.81
$16.89
52-Wochen-Spanne:
$8.58
$22.50
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Firmenname
Syndax Pharmaceuticals Inc
Sektor
Branche
Telefon
781-419-1400
Adresse
730 THIRD AVENUE, NEW YORK, MA
Vergleichen Sie SNDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
16.19 | 1.39B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-05 | Bestätigt | BTIG Research | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-10-25 | Eingeleitet | BofA Securities | Buy |
| 2023-10-11 | Eingeleitet | Goldman | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-11 | Eingeleitet | Guggenheim | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2023-01-03 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-28 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-04-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-15 | Eingeleitet | Goldman | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-25 | Eingeleitet | Citigroup | Buy |
| 2021-02-18 | Eingeleitet | B. Riley Securities | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-05-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-01-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Eingeleitet | FBR & Co. | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-10-07 | Eingeleitet | Guggenheim | Buy |
| 2016-03-28 | Eingeleitet | Citigroup | Buy |
| 2016-03-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-03-28 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
Tema Etfs LLC Buys Shares of 21,169 Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Nuveen LLC Takes Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Can a trend reversal in Syndax Pharmaceuticals Inc. lead to recoveryEarnings Growth Summary & Free Verified High Yield Trade Plans - Newser
Point72 Europe London LLP Takes Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
How high can Syndax Pharmaceuticals Inc. stock price go in 2025Market Growth Review & Consistent Profit Trading Strategies - Newser
Trexquant Investment LP Reduces Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Inc. recovery potential after sell offEarnings Growth Report & Trade Opportunity Analysis Reports - Newser
Syndax Pharmaceuticals, Inc. $SNDX Shares Sold by Wellington Management Group LLP - MarketBeat
Russell Investments Group Ltd. Has $1.45 Million Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Will Syndax Pharmaceuticals Inc. benefit from macro trendsWeekly Trend Recap & Free Technical Pattern Based Buy Signals - Newser
Statistical indicators supporting Syndax Pharmaceuticals Inc.’s strengthProfit Target & Accurate Intraday Trading Signals - Newser
Smart tools for monitoring Syndax Pharmaceuticals Inc.’s price actionPortfolio Return Report & Precise Trade Entry Recommendations - Newser
Signal strength of Syndax Pharmaceuticals Inc. stock in tech scannersWeekly Stock Report & Weekly Breakout Opportunity Watchlist - Newser
Intraday pattern recognizer results for Syndax Pharmaceuticals IncPrice Action & Real-Time Volume Trigger Notifications - Newser
Syndax Pharmaceuticals' Strategic Position in the Evolving Oncology Landscape - AInvest
Is a relief rally coming for Syndax Pharmaceuticals Inc. holdersQuarterly Trade Review & Reliable Breakout Forecasts - Newser
Is Syndax Pharmaceuticals Inc. still a buy after recent gainsEarnings Overview Summary & Smart Investment Allocation Tips - khodrobank.com
Momentum Indicator Shows Bearish Divergence in Syndax Pharmaceuticals Inc. getLinesFromResByArray error: size == 0 - thegnnews.com
Intraday pattern recognizer results for Syndax Pharmaceuticals Inc.2025 Support & Resistance & Stock Market Timing Techniques - Newser
Walleye Capital LLC Has $4.02 Million Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Will Syndax Pharmaceuticals Inc. continue its uptrendJuly 2025 Gainers & Weekly Return Optimization Alerts - Newser
Is Syndax Pharmaceuticals Inc. a cyclical or defensive stockAnalyst Downgrade & Low Risk Investment Opportunities - خودرو بانک
Predicting Syndax Pharmaceuticals Inc. trend using moving averagesTrade Ideas & Fast Moving Stock Watchlists - Newser
Wall Street Analysts Believe Syndax (SNDX) Could Rally 112.8%: Here's is How to Trade - sharewise.com
Understanding Syndax Pharmaceuticals Inc.’s price movementBuy Signal & Weekly Stock Performance Updates - Newser
Is It Too Late to Sell Syndax Pharmaceuticals Inc. getLinesFromResByArray error: size == 0 - thegnnews.com
Real time breakdown of Syndax Pharmaceuticals Inc. stock performanceQuarterly Portfolio Summary & High Accuracy Buy Signal Tips - Newser
Custom strategy builders for tracking Syndax Pharmaceuticals Inc.Trade Volume Summary & Fast Moving Market Watchlists - Newser
Sentiment analysis tools applied to Syndax Pharmaceuticals Inc.Earnings Overview Report & Low Drawdown Trading Techniques - Newser
Is this a good reentry point in Syndax Pharmaceuticals Inc.Earnings Growth Report & Free Community Consensus Stock Picks - Newser
Can trapped investors hope for a rebound in Syndax Pharmaceuticals Inc.July 2025 Snapshot & Capital Efficient Trading Techniques - Newser
What the charts say about Syndax Pharmaceuticals Inc. today2025 Institutional Moves & Weekly High Return Stock Forecasts - Newser
When is the best time to exit Syndax Pharmaceuticals Inc.July 2025 Selloffs & Free Real-Time Volume Trigger Notifications - Newser
Finanzdaten der Syndax Pharmaceuticals Inc-Aktie (SNDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Syndax Pharmaceuticals Inc-Aktie (SNDX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Podlesak Dennis | Director |
Aug 15 '25 |
Option Exercise |
7.20 |
19,200 |
138,240 |
210,963 |
| Podlesak Dennis | Director |
Aug 18 '25 |
Option Exercise |
7.20 |
19,200 |
138,240 |
210,963 |
| Podlesak Dennis | Director |
Aug 18 '25 |
Sale |
15.84 |
19,200 |
304,170 |
191,763 |
| Podlesak Dennis | Director |
Aug 15 '25 |
Sale |
15.54 |
19,200 |
298,408 |
191,763 |
| Podlesak Dennis | Director |
Aug 14 '25 |
Sale |
14.19 |
19,200 |
272,521 |
191,763 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):